abacavir/lamivudine/zidovudine

DRUG2 trials

Sponsors

ViiV Healthcare, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Conditions

HIV InfectionHIV-1 Infection

Phase 3

Study of Options for Second-Line Effective Combination Therapy (SELECT)

CompletedNCT01352715

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHIV-1 Infection

Start: 2012-03-13End: 2014-10-29Updated: 2021-08-05

Phase 4

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

CompletedNCT00038506

ViiV HealthcareHIV Infection

Start: 2002-03-31End: 2004-08-31Target: 100Updated: 2015-04-08

Related Papers

Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings

AIDS Care2021-01-238 citations

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

2016-04-1861 citations